Ion Beam Applications SA
Andrew Dike has a diverse work experience spanning multiple industries. Andrew started their career in 2010 as a Sales Manager at Cellular Sales. Andrew then worked as a Consultant at Yandex from February 2011 to October 2011 before joining McCloskey & Associates - Wealth Management as a Business Development Manager from September 2011 to May 2012. Andrew then worked at Sun Nuclear Corporation as a Support Specialist from May 2012 to March 2014. After that, they joined IBA Dosimetry as a Proton Dosimetry Sales Specialist from April 2014 to March 2016. In 2016, Andrew moved to IBA, where they held various roles such as Proteus®SERVICES Product Manager from March 2016 to February 2018, Sales Manager - Europe from January 2018 to January 2020, Sales Director - North & Central Europe from January 2020 to July 2022, and currently serves as the Sales Director - UK & Ireland | Central & Eastern Europe | Central Asia & Russia.
Andrew Dike earned their Bachelor of Arts degree in Russian Language, Culture, and Literature from the University of Florida in 2009. In the same year, they also studied Russian Language and Literature at Saint Petersburg State University. Later, in 2013-2016, they pursued a Master of Business Administration (MBA) at Durham University Business School.
Ion Beam Applications SA
4 followers
Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.